217 related articles for article (PubMed ID: 26121982)
1. Structure-Function Basis of Attenuated Inverse Agonism of Angiotensin II Type 1 Receptor Blockers for Active-State Angiotensin II Type 1 Receptor.
Takezako T; Unal H; Karnik SS; Node K
Mol Pharmacol; 2015 Sep; 88(3):488-501. PubMed ID: 26121982
[TBL] [Abstract][Full Text] [Related]
2. Current topics in angiotensin II type 1 receptor research: Focus on inverse agonism, receptor dimerization and biased agonism.
Takezako T; Unal H; Karnik SS; Node K
Pharmacol Res; 2017 Sep; 123():40-50. PubMed ID: 28648738
[TBL] [Abstract][Full Text] [Related]
3. Binding sites of valsartan, candesartan and losartan with angiotensin II receptor 1 subtype by molecular modeling.
Bhuiyan MA; Ishiguro M; Hossain M; Nakamura T; Ozaki M; Miura S; Nagatomo T
Life Sci; 2009 Jul; 85(3-4):136-40. PubMed ID: 19446572
[TBL] [Abstract][Full Text] [Related]
4. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state.
Miura S; Kiya Y; Kanazawa T; Imaizumi S; Fujino M; Matsuo Y; Karnik SS; Saku K
Mol Endocrinol; 2008 Jan; 22(1):139-46. PubMed ID: 17901125
[TBL] [Abstract][Full Text] [Related]
5. Valsartan ameliorates the constitutive adipokine expression pattern in mature adipocytes: a role for inverse agonism of the angiotensin II type 1 receptor in obesity.
Hasan AU; Ohmori K; Hashimoto T; Kamitori K; Yamaguchi F; Ishihara Y; Ishihara N; Noma T; Tokuda M; Kohno M
Hypertens Res; 2014 Jul; 37(7):621-8. PubMed ID: 24599011
[TBL] [Abstract][Full Text] [Related]
6. Divergent Spatiotemporal Interaction of Angiotensin Receptor Blocking Drugs with Angiotensin Type 1 Receptor.
Singh KD; Unal H; Desnoyer R; Karnik SS
J Chem Inf Model; 2018 Jan; 58(1):182-193. PubMed ID: 29195045
[TBL] [Abstract][Full Text] [Related]
7. Adrenal angiotensin II type 1 receptor biased signaling: The case for "biased" inverse agonism for effective aldosterone suppression.
Ferraino KE; Cora N; Pollard CM; Sizova A; Maning J; Lymperopoulos A
Cell Signal; 2021 Jun; 82():109967. PubMed ID: 33640432
[TBL] [Abstract][Full Text] [Related]
8. Long range effect of mutations on specific conformational changes in the extracellular loop 2 of angiotensin II type 1 receptor.
Unal H; Jagannathan R; Bhatnagar A; Tirupula K; Desnoyer R; Karnik SS
J Biol Chem; 2013 Jan; 288(1):540-51. PubMed ID: 23139413
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of Hormone Peptide Activation of a GPCR: Angiotensin II Activated State of AT
Singh KD; Unal H; Desnoyer R; Karnik SS
J Chem Inf Model; 2019 Jan; 59(1):373-385. PubMed ID: 30608150
[TBL] [Abstract][Full Text] [Related]
10. Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects.
Miura S; Karnik SS; Saku K
J Renin Angiotensin Aldosterone Syst; 2011 Mar; 12(1):1-7. PubMed ID: 20603272
[TBL] [Abstract][Full Text] [Related]
11. Multivalent ligand-receptor interactions elicit inverse agonist activity of AT(1) receptor blockers against stretch-induced AT(1) receptor activation.
Qin Y; Yasuda N; Akazawa H; Ito K; Kudo Y; Liao CH; Yamamoto R; Miura S; Saku K; Komuro I
Hypertens Res; 2009 Oct; 32(10):875-83. PubMed ID: 19662020
[TBL] [Abstract][Full Text] [Related]
12. Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor.
Zhang H; Unal H; Desnoyer R; Han GW; Patel N; Katritch V; Karnik SS; Cherezov V; Stevens RC
J Biol Chem; 2015 Dec; 290(49):29127-39. PubMed ID: 26420482
[TBL] [Abstract][Full Text] [Related]
13. Ligand-specific conformation of extracellular loop-2 in the angiotensin II type 1 receptor.
Unal H; Jagannathan R; Bhat MB; Karnik SS
J Biol Chem; 2010 May; 285(21):16341-50. PubMed ID: 20299456
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II cyclic analogs as tools to investigate AT
St-Pierre D; Cabana J; Holleran BJ; Besserer-Offroy É; Escher E; Guillemette G; Lavigne P; Leduc R
Biochem Pharmacol; 2018 Aug; 154():104-117. PubMed ID: 29684376
[TBL] [Abstract][Full Text] [Related]
15. Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan.
Miura S; Okabe A; Matsuo Y; Karnik SS; Saku K
Hypertens Res; 2013 Feb; 36(2):134-9. PubMed ID: 23034464
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling.
Du N; Feng J; Hu LJ; Sun X; Sun HB; Zhao Y; Yang YP; Ren H
Oncol Rep; 2012 Jun; 27(6):1893-903. PubMed ID: 22426690
[TBL] [Abstract][Full Text] [Related]
17. Class- and molecule-specific differential effects of angiotensin II type 1 receptor blockers.
Imaizumi S; Miura S; Yahiro E; Uehara Y; Komuro I; Saku K
Curr Pharm Des; 2013; 19(17):3002-8. PubMed ID: 23176212
[TBL] [Abstract][Full Text] [Related]
18. Identification of dual ligands targeting angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ by core hopping of telmisartan.
Zhang J; Liu X; Wang SQ; Liu GY; Xu WR; Cheng XC; Wang RL
J Biomol Struct Dyn; 2017 Sep; 35(12):2665-2680. PubMed ID: 27602589
[TBL] [Abstract][Full Text] [Related]
19. A small difference in the molecular structure of angiotensin II receptor blockers induces AT₁ receptor-dependent and -independent beneficial effects.
Fujino M; Miura S; Kiya Y; Tominaga Y; Matsuo Y; Karnik SS; Saku K
Hypertens Res; 2010 Oct; 33(10):1044-52. PubMed ID: 20668453
[TBL] [Abstract][Full Text] [Related]
20. Trans and Cis Conformations of the Antihypertensive Drug Valsartan Respectively Lock the Inactive and Active-like States of Angiotensin II Type 1 Receptor: A Molecular Dynamics Study.
Wang L; Yan F
J Chem Inf Model; 2018 Oct; 58(10):2123-2130. PubMed ID: 30212210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
